Table 4.

Univariate and multivariable analysis of disease free survival (DSS) and progression-free survival (PFS) in patients with renal cell carcinoma (RCC).

Feature	DSS				PFS
	Univariate		Multiivariable		Univariate		Multiivariable
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Age
(>55.2 vs. ≤55.2)	1.15 (0.46–2.87)	0.759	—	—	1.68 (1.00–2.79)	0.046	—	—
Sex
(male vs. female)	0.91 (0.33–2.55)	0.872	—	—	0.93 (0.53–1.63)	0.804	—	—
Clinical stage
(III/IV vs. I/II)	2.25 (0.85–5.97)	0.103	—	—	2.40 (1.34–4.30)	0.003	2.41 (1.48–3.91)	<0.001
Fuhrman grade
(III/IV vs. I/II)	3.70 (1.47–9.30)	0.005	2.83 (1.17–6.81)	0.020	1.73 (0.97–3.08)	0.063	—	—
Tumor size	1.22 (1.08–1.38)	0.001	1.68 (1.07–2.66)	0.024	1.04 (0.96–1.12)	0.354	—	—
MVI
(Present vs. Absent)	0.39 (0.14–1.04)	0.062	—	—	1.05 (0.94–1.16)	0.354	—	—
Nuclear OCT4 Expression
High vs. low	0.62 (0.20–1.88)		0.399	—	—	1.60 (0.94–2.72)	0.079	—
Nuclear NANOG Expression
High vs. low	1.00 (0.37–2.68)	0.986	—	—	1.38 (0.89–2.12)	0.141	—	—
Cytoplasmic NANOG Expression
High vs. low	1.00 (0.39–2.54)	0.996	—	—	1.86 (1.22–2.83)	0.004	1.58 (1.02–2.45)	0.041
OCT4 nuclear/NANOG nuclear
High vs. Other phenotypes	0.84 (0.30–2.35)	0.752	—	—	0.51 (0.32–0.82)	0.005	0.55 (0.34–0.90)	0.018
OCT4 nuclear/NANOG cytoplasmic
High vs. Other phenotypes	0.83 (0.33–2.08)	0.706	—	—	0.70 (0.46–1.64)	0.096	—	—

Abbreviations: HR hazard ratio; CI confidence interval MVI; Microvascular invasion.

Values in bold are statistically significant.

The variables with P value less than 0.2 were included in multivariable analyses.